Related Experiment Video
Updated: Jul 12, 2025

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Proteomic profiling and network biology of colorectal cancer liver metastasis
Rubén A Bartolomé1, J Ignacio Casal1
1Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain.
Introduction:
Tissue-based proteomic studies of colorectal cancer (CRC) metastasis have delivered fragmented results, with very few therapeutic targets and prognostic biomarkers moving beyond the discovery phase. This situation is likely due to the difficulties in obtaining and analyzing large numbers of patient-derived metastatic samples, the own heterogeneity of CRC, and technical limitations in proteomics discovery. As an alternative, metastatic CRC cell lines provide a flexible framework to investigate the underlying mechanisms and network biology of metastasis for target discovery.
Areas Covered:
In this perspective, we comment on different in-depth proteomic studies of metastatic versus non-metastatic CRC cell lines. Identified metastasis-related proteins are introduced and discussed according to the spatial location in different cellular fractions, with special emphasis on membrane/adhesion proteins, secreted proteins, and nuclear factors, including miRNAs associated with liver metastasis. Moreover, we analyze the biological significance and potential therapeutic applications of the identified liver metastasis-related proteins.
Expert Opinion:
The combination of protein discovery and functional analysis is the only way to accelerate the progress to clinical translation of the proteomic-derived findings in a relatively fast pace. Patient-derived organoids represent a promising alternative to patient tissues and cell lines, but further optimizations are still required for achieving solid and reproducible results.
Insights
Metastatic colorectal cancer (CRC) cell lines offer a flexible model for proteomic discovery of metastasis-related proteins. This approach aids in identifying potential therapeutic targets and biomarkers for liver metastasis, overcoming limitations of patient-derived tissues.
Area of Science:
- Proteomics
- Cancer Biology
- Molecular Oncology
Background:
- Proteomic studies of colorectal cancer (CRC) metastasis yield fragmented results, hindering therapeutic target and biomarker discovery.
- Challenges include sample acquisition, CRC heterogeneity, and proteomic technical limitations.
- Metastatic CRC cell lines offer a viable alternative for investigating metastasis mechanisms and network biology.
Purpose of the Study:
- To review proteomic studies of metastatic versus non-metastatic CRC cell lines.
- To identify and discuss metastasis-related proteins, focusing on cellular fractions and liver metastasis.
- To analyze the biological significance and therapeutic potential of identified proteins.
Main Methods:
- In-depth proteomic analysis of metastatic and non-metastatic CRC cell lines.
- Categorization of identified proteins by cellular location (membrane, secreted, nuclear).
- Analysis of microRNAs (miRNAs) associated with liver metastasis.
Main Results:
- Identification of key proteins involved in colorectal cancer metastasis.
- Emphasis on membrane/adhesion proteins, secreted proteins, and nuclear factors.
- Insights into proteins and miRNAs linked to liver metastasis.
Conclusions:
- Combining protein discovery with functional analysis is crucial for clinical translation.
- Metastatic CRC cell lines provide a valuable framework for identifying therapeutic targets.
- Patient-derived organoids show promise but require further optimization for reproducible results.
More Related Videos
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
10:59Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
Published on: February 7, 2025